Teens Are Suffering from Severe Period Pain--Too Many Have Undiagnosed Endometriosis
ROCKVILLE, Md., April 15, 2025 /PRNewswire/ -- A leading gynecologic surgeon is sounding alarms over the growing number of teenage girls arriving at her clinic with symptoms of endometriosis—a painful, complex condition that can begin with a girl's first period. Dr. Natalya Danilyants, a board-certified gynecologic hyper-specialist, has been practicing for 17 years at the Center for Innovative GYN Care (CIGC), where the trend is increasing. Many teens go years without proper treatment, leading to worsening symptoms, delayed diagnoses, disruptions to daily life, and long-term risks to their fertility and overall health.
"Endometriosis doesn't wait until adulthood," said Dr. Danilyants, co-founder of the CIGC. "We're seeing more young patients who've been told their pain is 'just bad periods.' In reality, it's endometriosis that's been left untreated, causing them to suffer in silence, miss school, and lose out on major milestones during the most formative years of their lives."
What Is Endometriosis?
Endometriosis occurs when cells similar to those of the uterine lining grow outside the uterus—on the ovaries, fallopian tubes, bladder, or other pelvic organs. These cells respond to hormonal changes, building up and shedding without a way to exit the body. This leads to chronic inflammation, pain, and in severe cases, scar tissue that can damage organs and impact fertility.
Why Early Diagnosis and Specialist Treatment Matters
Delaying surgery increases the risk of complications including infertility and organ damage, which is why patients from across the U.S. and all over the world travel to CIGC's private, outpatient surgical centers to receive life-changing treatment. "Even with proper care, endometriosis can lead to infertility," said Dr. Danilyants. "Delays, misdiagnosis, or improper surgical removal only make that risk worse."
At CIGC, hyper-specialists use DualPortGYN®, a minimally invasive surgical technique developed in-house that combines just two to three small, cosmetically placed incisions with Retroperitoneal Excision Therapy (RET). This advanced approach allows for:
Complete removal of endometriosis lesions
Immediate pain relief
Dramatically improved fertility outcomes
Minimal scarring and the fastest possible recovery
Unlike many providers who claim expertise in treating this condition, CIGC never uses ablation or burning techniques, which often leave disease behind. CIGC also doesn't use robotic surgery, avoiding the added costs to patients and extra incisions—robotic procedures typically require five incisions, while CIGC uses just two.
Highest Success Rates Backed by Research
CIGC's approach is driven by superior patient experience and outcomes. Its surgeons are dedicated exclusively to GYN surgery and perform a high volume of complex procedures each year. That surgical focus allows for continuous refinement of techniques, which leads to:
Lower complication rates
Faster recovery
High patient satisfaction
These results aren't anecdotal. Our high success rates and low complication rates are published in peer-reviewed medical journals, allowing both providers and the public to see exactly how CIGC is improving outcomes — even in the most complex cases.
Choosing the Right Surgeon Matters—Especially for Teens
Our surgical team is made up of true GYN hyper-specialists, not general OBGYNs. They are trained in advanced gynecologic surgery using oncology techniques that demand the highest level of precision and expertise.
"Teens deserve better than birth control and vague reassurances," said Dr. Danilyants. "They deserve a real diagnosis, fertility-preserving treatment, and long-term relief. That's what we're here to provide."
For more information or to schedule a consultation, visit www.innovativegyn.com.
About The Center for Innovative GYN Care (CIGC)
The Center for Innovative GYN Care (CIGC) is a recognized leader in minimally invasive gynecologic surgery, specializing in advanced, fertility-sparing techniques like LAAM and DualPortGYN®, which offer significantly lower complication rates, minimal scarring, and faster recovery. For over 20 years, CIGC's expert team has been treating complex gynecologic conditions and improving health outcomes for teens and women through highly personalized, evidence-based care.
Media Contact:
Jasmin Ramsey1 888-787-4379, opt 1
View original content to download multimedia:https://www.prnewswire.com/news-releases/teens-are-suffering-from-severe-period-paintoo-many-have-undiagnosed-endometriosis-302427742.html
SOURCE The Center for Innovative GYN Care (CIGC)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab Veterinary Inc., a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that ElenaVet™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled "Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study," appears in Frontiers in Veterinary Science (DOI 10.3389/fvets.2025.1519881). Key findings 17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks. Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI). 90% of dogs met the study's pre-defined "treatment success" criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of "good/excellent" rose from 1 to 12 dogs. First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6. No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment. Executive & scientific commentary"ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use," said Robert Devlin, general manager of CureLab Veterinary. "These results put us on a clear path toward larger, controlled trials and eventual U.S. approval." "The p62 plasmid dampens multiple inflammatory pathways simultaneously," added Vladimir Gabai, PhD, chief science officer and lead author of the study. "Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required." Addressing a widespread unmet needOsteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or "as-needed" injections, once dose-frequency optimization studies are complete. Next stepsCureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis. About CureLab Veterinary Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit Investigational status / safe-harbor statementElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties. Media contactTim Cox | ZingPR for CureLab Veterinary | tim@ View original content to download multimedia: SOURCE CureLab Veterinary Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio